-
JANE CHEN
Partner·Shanghai
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MS. CHEN IS A CORPORATE PARTNER IN OUR SHANGHAI OFFICE, SPECIALIZING IN CAPITAL MARKETS, PRIVATE EQUITY, AND CORPORATE AND M&A.
Education
East China University of Political Science and Law, School of Law, LL.B.
Professional Qualification
Admitted to practice in the PRC
Work Language
Chinese
English
Professional Background
Ms. Chen joined the Shanghai Office of Fangda Partners in 2022. She is a member of the Securities Business Research Committee of the Shanghai Bar Association.
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Acted for Lead Show (603272.SH) as issuer’s counsel in its A-share IPO
- Acted for Huaertai (001217.SZ) as issuer’s counsel in its A-share IPO
- Acted for Chenguang New Materials (605399.SH) as issuer’s counsel in its A-share IPO
- Acted for Sanyou Medical (688085.SH) as issuer’s counsel in its A-share IPO
- Acted for Hainan Mining (601969.SH) as issuer’s counsel in its A-share IPO
- Acted for Universal Scientific (601231.SH) as issuer’s counsel in its A-share IPO
- Acted for WUS Printed (002463.SZ) as issuer’s counsel in its A-share IPO
- Acted for MicuRx Pharmaceutical (Registered) as issuer’s counsel in its A-share IPO
- Acted for Universal Scientific (601231.SH) as issuer’s counsel in its private share placement
- Acted for Yunnan Salt and Chemical (002053.SZ) as issuer’s counsel in its private share placement
- Acted for Anjoy Foods (603345.SZ) as issuer’s counsel in its convertible debt projects
- Acted for NovelBeam (688677.SH) as underwriter’s counsel in its A-share IPO
- Acted for Endovascular (688016.SH) as underwriter’s counsel in its A-share IPO
- Acted for HCFA (688320.SH) as underwriter’s counsel in its A-share IPO
- Acted for Tuya Smart (NYSE: TUYA) as PRC counsel in its NYSE IPO
- Acted for Junshi Bio (1877.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Fosun Pharma (2196.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Sinopharm (1099.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Gland Pharma (NSE: GLAD) as PRC counsel in its spin-off from Fosun Pharma and its listing in India
- Acted for Wuxi Apptec (603259.SH and 2359.HK) as underwriters' counsel in its A-share and H-share offering
- Acted for Henlius (2696.HK) as underwriters' counsel in its H-share IPO
- Acted for Ark Bio as underwriters' counsel in its H-share IPO
- Advised Endovascular, Sanyou Medical, Junshi Bio, Anjoy Foods, Techmation, Haid Group, WUS, and Fosun Pharma on general corporate matters
- Represented CSC Shipping in issuing shares and paying cash to purchase Boya Technology and in raising matching funds
- Represented China Trade Logistics in issuing shares and paying cash to purchase Zhongte Logistics and in raising matching funds
- Represented Anjing Food in its acquisition of Hongye Aquatic
- Represented Akcome Group in its acquisitions of MSH Insurance Company in France and Zhenjing Clinic in the US
- Represented Monfali in its acquisition of all shares in Ojiahua, a listed company in Malaysia
- Represented China Trade Logistics in its cash acquisition of Dexiang Logistics
- Represented Hongxun Technology in its investment in Dongguan Zhiyin
- Represented Sanyou Medical in its acquisition of Shuimu Tianpeng
- Represented Haida Group in its acquisitions of Depot and other companies
- Represented American Warburg Pincus in its investments in Sida Restaurant Group, King Mother and Baby Products Retailer, and Red Star Macalline
- Represented Linxin Capital in its investments in Canxin, Core Long March and Junxin Electronics
- Represented Juntong Capital in its investments in Hongsoft Technology, Lanqi Technology and Broadcom Technology
- Represented True Gold Fund in its investment in Shangxun Information
- Represented Ping An Trust in its investment in Xi'an Ruilian
- Represented Huagai Capital and Junlian Capital in their investments in the Series C financing of Motorcomm and in the Series A+ and Series B financing of MicuRx Pharmaceutical, a leading mother and baby e-commerce company
- Represented Xinhua Capital in its investments in Henlius and other companies
OTHER INFORMATION
- Participated in the compilation of "Practice of Securities Law Practice for Lawyers" published by Law Press·China
- Member of the Securities Business Research Committee of the Shanghai Bar Association
- Member of the Lujiazui-Shanghai No.2 Branch Committee of The Revolutionary Committee of the Chinese Kuomintang
